News
ZLAB
21.54
-0.46%
-0.10
Novocure climbs after late-stage win for lung cancer therapy
Seeking Alpha · 1d ago
Zai Lab (ZLAB) Gets a Buy from Cantor Fitzgerald
TipRanks · 1d ago
Zai Lab publishes 2025 ESG report
PUBT · 3d ago
Zai Lab publishes 2025 annual report
PUBT · 3d ago
Zai Lab announces annual shareholder meeting
PUBT · 3d ago
Weekly Report: what happened at ZLAB last week (0420-0424)?
Weekly Report · 5d ago
CICC Sticks to Its Buy Rating for Zai Lab Ltd (1ZLB)
TipRanks · 04/25 00:26
Guotai Haitong Sticks to Their Buy Rating for Zai Lab Ltd (1ZLB)
TipRanks · 04/24 01:50
UBS Sticks to Its Buy Rating for Zai Lab Ltd (1ZLB)
TipRanks · 04/24 00:25
Zai Lab to host earnings call after releasing first-quarter results
PUBT · 04/23 08:39
Jefferies Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)
TipRanks · 04/23 00:27
Cantor Fitzgerald Remains a Buy on Zai Lab (ZLAB)
TipRanks · 04/21 13:25
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Climb Bio (CLYM) and Zai Lab (ZLAB)
TipRanks · 04/21 12:20
Weekly Report: what happened at ZLAB last week (0413-0417)?
Weekly Report · 04/20 09:46
Zai Lab publishes AACR presentation highlighting DLL3 ADC ZL-1310 in SCLC brain metastases
PUBT · 04/20 02:57
Zai Lab presents new preclinical data on ZL-1503
TipRanks · 04/19 17:06
Zai Lab starts Phase 1/1b trial of ZL-1503 bispecific antibody in atopic dermatitis
PUBT · 04/18 13:00
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Barchart · 04/18 08:00
Zai Lab to present zocilurtatug pelitecan clinical data at AACR meeting
TipRanks · 04/17 19:11
Zai Lab Announces Clinical Data Indicating Zoci, DLL3-Targeting ADC, Provides Rapid And Robust Intracranial Responses In Patients With Previously Treated ES-SCLC And Brain Metastases And Other NECs
Benzinga · 04/17 19:06
More
Webull provides a variety of real-time ZLAB stock news. You can receive the latest news about Zai Lab Limited through multiple platforms. This information may help you make smarter investment decisions.
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.